Investors

Growing Shareholder Value

Press Releases

Impella Featured as an Innovative Technology at U.S. Capitol Event Showcasing Improvements to Women’s Health

Jun 13, 2019
Read More

Abiomed to Present at Upcoming Investor Conferences

May 29, 2019
Read More

FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval

May 21, 2019
Read More

National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

May 21, 2019
Read More

Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes

May 16, 2019
Read More

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

May 13, 2019
Read More

FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial

May 02, 2019
Read More

Abiomed Announced Q4 FY 2019 Revenue of $207 Million and 31.6% Operating Margin

May 02, 2019
Read More

Clinical Data Highlights Advantages of Protected PCI to Enable Complete Revascularization and Improved Patient Quality of Life

Apr 23, 2019
Read More

Abiomed Fourth Quarter Fiscal 2019 Earnings and Conference Call Notification

Apr 11, 2019
Read More
View all